A researcher at UPMC's Hillman Cancer Center has  received a $75,000 American Lung Association grant to look into the way signals from tumor cells might affect immunotherapy’s effectiveness in fighting lung squamous cell cancer. The grant is renewable for an additional year, for a total of $150,000.

"Our project focuses on tackling resistance to immunotherapy in lung squamous cell carcinoma, a major challenge in lung cancer treatment," said grant recipient Riyue Bao, an associate professor of medicine and co-director of Bioinformatics at the Hillman Cancer Center. "Our research addresses the urgent need for more effective therapies for lung cancer patients whose tumors resist immunotherapy."

In total, the American Lung Association Research Institute announced a $22 million research investment in the past year, making it one of the largest programs in the country focused on lung health. The Lung Association funded 139 research grants, including the Airways Clinical Research Centers (ACRC), and strategic research partnerships focused on finding ways to identify, treat and cure lung disease.

Bao’s project will focus on studying a tumor pathway called p38 MAPK that may help tumors resist a common immunotherapy called immune checkpoint inhibitors (ICI). Understanding this pathway could help make ICI work better and find new treatments for patients.

Advertise with us

Essentially, the team is hoping to stop certain cancer mechanisms from blocking T-cells, the immune system's primary defenders, from doing their job of infiltrating and attacking tumors.

"We aim to develop new strategies to break down these barriers, giving patients, especially those with few treatment options, a better chance at successful treatment," Bao said.

Bao said her research lab has long-standing collaborations with experts in immuno-oncology and immunotherapy trials, disease-specific and surgical experts, and precision oncology, including Jason Luke, Laura Stabile, Rajeev Dhupar, Renee Levesque and Adrian Lee, all researchers and doctors at UPMC.

"What makes this project especially impactful is our collaborative, multidisciplinary team of clinicians, surgeons, pathologists, bioengineers, and computational scientists, all working together to translate these findings into real-world therapies. Through collaborative science, we drive the research discoveries from lab to the clinic,” Bao said.

“For the past 10 years, my research program has centered on understanding why some tumors respond to immunotherapy while others do not,” Bao said, adding that “lung cancer remains the leading cause of cancer-related deaths, and this issue is particularly pressing here in Western Pennsylvania, where lung cancer rates are among the highest in the country. With our research lab based in Pittsburgh and UPMC Hillman Cancer Center, I feel a strong connection to addressing this regional health burden.”

Advertise with us

Cutting-edge tech

Bao’s team will use cutting-edge technology to study patient data in a more detailed and accurate way:

  • Spatial imaging: By creating detailed 3D pictures of tissues, it is easier to see how different cells are arranged and interact.
  • Multi-omics profiling: This is similar to being able to look at a patient’s biological "blueprints" — genes, proteins, and more — to understand how their body works or reacts to treatments.
  • Patient-derived organoids (PDOs): These are mini versions of a patient’s tumors grown in the lab and used to test how treatments might work before trying them on the actual patient.
  • AI-driven radiomics: Artificial intelligence will be used to analyze CT scans and find patterns that humans might miss, helping predict how well a treatment is working.

In short, the grant funding will enable the team to combine tools to get a better understanding of how treatments affect patients. Using these technologies will increase the team’s precision in analyzing and interpreting the data in the hopes of revealing new targets in battling the tumors. They’ll be able to test therapies via simulation, which could potentially identify new treatment strategies and also personalize treatments for individual patients so that they receive therapies tailored to their specific needs with presumably the highest rate of success.

“One of the greatest challenges in advancing lung health research is the complexity of tumor-immune interactions, compounded by the variability in how patients respond to treatments,” Bao said. “These factors make it difficult to predict which therapies will be effective for individual patients.”

Bao said patients who could potentially benefit most from the research are those who have exhausted standard treatment options.

“Many of these patients come from underserved or vulnerable communities, where access to innovative treatments is often limited. By combining cutting-edge research with a collaborative clinical translation, we aim to develop therapies that are not only more effective but also more accessible,” Bao said.

Advertise with us

“Our ultimate goal is to ensure that our breakthroughs translate into meaningful improvements in survival and quality of life for patients who face the greatest challenges in accessing effective care.”

Looking ahead

Bao said this project is laying the foundation for her larger vision of advancing precision and tailormade treatment options by developing next-generation cancer therapies.

“Moving forward, we plan to expand our transdisciplinary collaborations across clinicians, computational scientists, engineers, and industry partners to translate our findings into clinical trials. These efforts will focus on uncovering novel therapeutic targets and understanding their role in overcoming immunotherapy resistance. Ultimately, our goal is to create a transformative framework for lung cancer care that delivers personalized and effective therapies for patients.”